Neurosoft Bioelectronics
Geneva, Switzerland
◆ Total Raised
$7.5M
◆ Stage
seed
◆ Location
Geneva, Switzerland
◆ Founded
2020
◆ Team size
11-50
◆ Links
◆ About Neurosoft Bioelectronics
Swiss neurotechnology company developing minimally invasive brain-computer interface (BCI) platforms using soft and stretchable neural interfaces.
◆ What sets it apart
Their soft, stretchable electrodes are designed to be far more compliant than conventional neural interfaces, enabling minimally invasive full-cortex access without penetrating brain tissue.
◆ Sectors
◆ Business
Modelhardware
CustomerHospitals, neurosurgeons, and clinical research centers treating neurological disorders such as epilepsy, tinnitus, and brain tumors
◆ Notable
- Raised a $7.5 million oversubscribed seed round in 2026
- Tested its 64-channel soft brain interface in the first two human patients during epilepsy surgery in 2025
- Protected by more than 25 patents
- Published in more than 25 peer-reviewed articles
◆ Backing funds on Raise
◆ Funding rounds
20 May 2026
Led by Skybound Venture Capital
With Protocol Labs, IAG Capital Partners, Connecticut Innovations
◆ Explore the market
◆ FAQ
What does Neurosoft Bioelectronics do?
Swiss neurotechnology company developing minimally invasive brain-computer interface (BCI) platforms using soft and stretchable neural interfaces.
Where is Neurosoft Bioelectronics based?
Neurosoft Bioelectronics is based in Geneva, Switzerland, founded in 2020.
How much has Neurosoft Bioelectronics raised?
Neurosoft Bioelectronics has raised $7.5M in tracked funding and is currently at the seed stage.
Who has invested in Neurosoft Bioelectronics?
Investors in Neurosoft Bioelectronics include Skybound Venture Capital.